50 rue de Dijon
About InventivaInventiva is a biopharmaceutical company with several drug candidates at clinical and preclinical stage whose objective is to develop and provide patients with new therapies. The focus of the company’s research and developmentdepartment targets three promising areas, namely fibrotic diseases, the treatment of certain forms of lysosomal diseases and oncology with a priority for the development of indications for orphan diseases for which the unmet medical need and the regulations in force allow an accelerated development.
Founder and CEO: Frédéric Cren
Founder and CSO: Pierre Broqua
CFO: Jean Volatier
CMO: Jean-Louis Abitbol
Please click here for Inventiva job opportunities.
Please click here for clinical trial information.
Tweets by Inventiva Pharma
32 articles with Inventiva
10/3/2019Companies from across the globe share information on their business and pipelines.
9/26/2019Companies from across the globe share updates on their business and pipelines.
9/12/2019Companies and organizations from across Europe, Asia and North America share updates on their business and pipelines.
9/5/2019Companies from across Europe and Asia share updates on their business and pipelines.
8/29/2019Companies from across the globe provide updates on their business and pipelines.
8/22/2019Companies from across the globe provide updates on their business and pipelines.
6/13/2019Companies from across the globe share business and pipeline updates.
Companies across Europe and Asia provide information about deal, clinical trials and more, with news from Synaptive Medical, Epic, Inventiva, Velabs, and more.
Shares of France-based Inventiva have plunged more than 45 percent after the company reported that its experimental treatment for a rare autoimmune disease failed to hit primary and secondary endpoints in a mid-stage trial.
Inventiva today announced that Frédéric Cren, CEO of Inventiva, will present at two upcoming investor conferences.
Revenues of €6.0 million, an increase of 4.6% compared to 2016
Inventiva announced that it has completed the enrollment of its Phase IIb FASST (For A Systemic Sclerosis Treatment) trial in Systemic Sclerosis (SSc) with lanifibranor, formerly known as IVA337.
Inventiva And AbbVie Extend Agreement To Discover New Potent Orally-Available Small Molecule Ror? Inverse Agonist Drug Candidates
Inventiva Announces Exercise Of Option By Boehringer Ingelheim To Jointly Develop Potential New Treatments For Idiopathic Pulmonary Fibrosis (IPF)
Inventiva To Present New Data On IVA337 At The 15th International Workshop On Scleroderma Research In Pittsburgh, USA
Inventiva Announces New Compelling Data On Odiparcil / IVA336 To Be Presented At MPS Society National Conference